Research output: Contribution to journal › Article › peer-review
A Multi-Level miRNA Regulatory Network Associated with IRF1 Expression in Non-Small Cell Lung Cancer : In Silico Identification of Candidate Biomarkers for Immunotherapy Response. / Karaseva, Dariya V.; Perevalova, Alina M.; Kalinina, Tatiana S. et al.
In: International Journal of Molecular Sciences, Vol. 27, No. 12, 5192, 08.06.2026.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - A Multi-Level miRNA Regulatory Network Associated with IRF1 Expression in Non-Small Cell Lung Cancer
T2 - In Silico Identification of Candidate Biomarkers for Immunotherapy Response
AU - Karaseva, Dariya V.
AU - Perevalova, Alina M.
AU - Kalinina, Tatiana S.
AU - Kononchuk, Vladislav V.
AU - Kozlov, Vadim V.
AU - Gulyaeva, Lyudmila F.
AU - Pustylnyak, Vladimir O.
N1 - Karaseva, D.V.; Perevalova, A.M.; Kalinina, T.S.; Kononchuk, V.V.; Kozlov, V.V.; Gulyaeva, L.F.; Pustylnyak, V.O. A Multi-Level miRNA Regulatory Network Associated with IRF1 Expression in Non-Small Cell Lung Cancer: In Silico Identification of Candidate Biomarkers for Immunotherapy Response. Int. J. Mol. Sci. 2026, 27, 5192. https://doi.org/10.3390/ijms27125192 This research was funded by the Russian Science Foundation, grant number 25-25-00647.
PY - 2026/6/8
Y1 - 2026/6/8
N2 - Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced non-small cell lung cancer (NSCLC). However, the limited predictive value of PD-L1 expression as a biomarker underscores the urgent need for more reliable predictors of ICI response. Interferon regulatory factor 1 (IRF1) is a transcription factor that lies downstream of interferon-γ signaling and directly regulates CD274 (PD-L1) transcription. Here, we performed a comprehensive bioinformatic analysis to identify microRNAs (miRNAs) that may be associated with IRF1 expression in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC). Using data from The Cancer Genome Atlas (TCGA), we identified 20 miRNAs whose expression levels consistently and negatively correlated with IRF1 mRNA levels in both LUAD and LUSC. Among these, only hsa-miR-301b possesses conserved binding sites in the 3′UTR of IRF1 mRNA, suggesting direct post-transcriptional repression. For the remaining 19 miRNAs, we hypothesized an indirect mechanism of action. Further analysis revealed that hsa-miR-183 and hsa-miR-141 may target the transcription factor genes NFKB1 and STAT4, respectively, both of which positively correlate with IRF1 expression and are themselves associated with improved survival in ICI-treated patients. This study delineates a multi-layer miRNA regulatory network associated with IRF1 expression in NSCLC and identifies hsa-miR-301b, hsa-miR-183 and hsa-miR-141 as candidate upstream regulators of IRF1. Direct survival analysis for these miRNAs in ICI-treated cohorts was not feasible due to the lack of publicly available miRNA-seq data with treatment annotations; therefore, their clinical predictive value remains hypothetical, and experimental validation is required to assess their potential as predictors of ICI response.
AB - Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced non-small cell lung cancer (NSCLC). However, the limited predictive value of PD-L1 expression as a biomarker underscores the urgent need for more reliable predictors of ICI response. Interferon regulatory factor 1 (IRF1) is a transcription factor that lies downstream of interferon-γ signaling and directly regulates CD274 (PD-L1) transcription. Here, we performed a comprehensive bioinformatic analysis to identify microRNAs (miRNAs) that may be associated with IRF1 expression in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC). Using data from The Cancer Genome Atlas (TCGA), we identified 20 miRNAs whose expression levels consistently and negatively correlated with IRF1 mRNA levels in both LUAD and LUSC. Among these, only hsa-miR-301b possesses conserved binding sites in the 3′UTR of IRF1 mRNA, suggesting direct post-transcriptional repression. For the remaining 19 miRNAs, we hypothesized an indirect mechanism of action. Further analysis revealed that hsa-miR-183 and hsa-miR-141 may target the transcription factor genes NFKB1 and STAT4, respectively, both of which positively correlate with IRF1 expression and are themselves associated with improved survival in ICI-treated patients. This study delineates a multi-layer miRNA regulatory network associated with IRF1 expression in NSCLC and identifies hsa-miR-301b, hsa-miR-183 and hsa-miR-141 as candidate upstream regulators of IRF1. Direct survival analysis for these miRNAs in ICI-treated cohorts was not feasible due to the lack of publicly available miRNA-seq data with treatment annotations; therefore, their clinical predictive value remains hypothetical, and experimental validation is required to assess their potential as predictors of ICI response.
KW - IRF1
KW - NFKB1
KW - PD-L1
KW - STAT4
KW - biomarker
KW - immune checkpoint inhibitors
KW - miR-141
KW - miR-183
KW - miR-301b
KW - microRNA
KW - non-small cell lung cancer
KW - IRF1
KW - микроРНК
KW - немелкоклеточный рак легкого
KW - ингибиторы контрольных точек иммунного ответа
KW - PD-L1
KW - биомаркер
KW - miR-301b
KW - miR-183
KW - miR-141
KW - NFKB1
KW - STAT4
UR - https://www.mendeley.com/catalogue/ee4c1b2e-1484-3994-b8a0-7cf0fce3a83e/
UR - https://www.scopus.com/pages/publications/105043388874
U2 - 10.3390/ijms27125192
DO - 10.3390/ijms27125192
M3 - Article
C2 - 42352916
VL - 27
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
SN - 1661-6596
IS - 12
M1 - 5192
ER -
ID: 85506906